Camber Capital Management’s Keryx Biopharmaceuticals Inc KERX Stock Holding History

Camber Capital Management’s Portfolio KERX Stock Details KERX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2015 Q3	–	Sell	-500,000	Closed	-$4.99M	–	52
2015 Q2	$4.99M	Sell	500,000 -2,500,000	-83%	-$26.8M	0.34%	40
2015 Q1	$38.2M	Hold	3,000,000	–	–	2.73%	15
2014 Q4	$42.5M	Sell	3,000,000 -500,000	-14%	-$7.75M	2.82%	13
2014 Q3	$48.1M	Buy	3,500,000 +500,000	+17%	+$7.65M	4.52%	9
2014 Q2	$46.1M	Buy	3,000,000 +1,750,000	+140%	+$24.8M	3.02%	11
2014 Q1	$21.3M	Buy	+1,250,000	New	+$18.9M	1.67%	21

Other funds holding KERX

Baupost Group Boston, Massachusetts $5.42B AUM 22.93% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

Franklin Resources San Mateo, California $462B AUM 39.16% 1-Year Est. Return

ACM

Abrams Capital Management Boston, Massachusetts $5.48B AUM 3.63% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return

ORI

Oak Ridge Investments Chicago, Illinois $1.77B AUM 63.16% 1-Year Est. Return

BIT

BlackRock Institutional Trust San Francisco, California $675B AUM 16.07% 1-Year Est. Return

BFA

BlackRock Fund Advisors San Francisco, California $542B AUM 18.13% 1-Year Est. Return

ACM

Apex Capital Management Dayton, Ohio $4.54B AUM 1.74% 1-Year Est. Return

Camber Capital Management's KERX Position: Q3 2015 in Review

Camber Capital Management sold out of Keryx Biopharmaceuticals Inc (KERX) in Q3 2015, closing a stake of 500,000 shares — an estimated $4.99M sold.

Camber Capital Management first reported a position in KERX in Q1 2014 and held it in 6 quarters. The position peaked at $48.1M in Q3 2014. 138 funds tracked by Wall St. Rank hold KERX as of Q3 2015.

Camber Capital Management reported no remaining Keryx Biopharmaceuticals Inc position as of Q3 2015 after selling out during the quarter.
Camber Capital Management sold 500,000 Keryx Biopharmaceuticals Inc shares in Q3 2015, an estimated $4.99M.
Camber Capital Management first reported a position in Keryx Biopharmaceuticals Inc in Q1 2014 and held it in 6 quarters.
Camber Capital Management's Keryx Biopharmaceuticals Inc position peaked at $48.1M in Q3 2014.
138 funds tracked by Wall St. Rank held Keryx Biopharmaceuticals Inc as of Q3 2015.

Based on Camber Capital Management's 13F filing for Q3 2015, filed 13 Nov 2015.